PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Molnupiravir→

Molnupiravir PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
2492423-29-5
Molecular formula
C13H19N3O7
Molecular weight
329.31 g/mol
Drug class
Antiviralnucleoside analogue prodrug targeting SARS-CoV-2 RNA polymerase
Mechanism of action
A prodrug converted intracellularly to N-hydroxycytidine triphosphate, which is incorporated by viral RNA-dependent RNA polymerase and causes accumulation of errors in the viral genome (viral error induction or lethal mutagenesis).
Indications / reported uses
  • Treatment of mild-to-moderate COVID-19 in adults at increased risk of progression when alternative authorised treatment options are not appropriate, subject to current local authorisation and product-label criteria.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1b0da643-ab23-4a0b-a9ec-a434522446d0 · https://pmc.ncbi.nlm.nih.gov/articles/PMC10851176/

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Molnupiravir PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Molnupiravir Permitted Daily Exposure (PDE) report (the Molnupiravir PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Molnupiravir Occupational Exposure Limit (OEL) report (the Molnupiravir OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.